Item 8.01. Other Events.

On February 1, 2023, Sesen Bio, Inc. (the "Company") announced that the U.S. District Court for the Southern District of New York (the "Court") issued an order on January 31, 2023 granting final approval of the settlement of the consolidated shareholder class action captioned In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the "Securities Litigation"), in accordance with the Stipulation and Agreement of Settlement that the Company disclosed in a Current Report on Form 8-K dated August 17, 2022. As previously disclosed in the Company's Current Report on Form 8-K dated September 29, 2022, the Court issued an order on September 28, 2022 granting preliminary approval of the settlement of the Securities Litigation.

Information concerning the settlement of the Securities Litigation was sent directly to potential class members by the claims administrator and was posted on a website (www.sesenbiosecuritiessettlement.com) developed for purposes of providing information about the settlement. Information contained in or accessible through that website does not constitute part of, and is not incorporated into, this Current Report on Form 8-K.

The Company also disclosed in a Current Report on Form 8-K dated November 9, 2022, that the U.S. District Court for the District of Massachusetts granted final approval of the settlement of the previously disclosed consolidated derivative lawsuits captioned In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538, the derivative lawsuit captioned Tang v. Sesen Bio, Inc., et al., Case No. 2281-cv-00135 and other potential related derivative claims (collectively, the "Derivative Litigation"), in accordance with the Stipulation of Settlement that the Company disclosed in a Current Report on Form 8-K dated August 30, 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses